Investment
Features
FeesSafety
Academy
More
Pluang+

Compare The Coca-Cola Co K (KO) vs Viatris Inc (VTRS) Price & Performance

The Coca-Cola Co KTrade
Viatris IncTrade

Price performance (Past 24H)

Key statistics

The Coca-Cola Co K vs Viatris Inc — how do they compare? The Coca-Cola Co K trades at $88.05 (market cap $377.63B), while Viatris Inc trades at $17.64 (market cap $20.03B). The key difference: The Coca-Cola Co K is far larger — about 18.9× Viatris Inc's market cap, and Viatris Inc pays the higher dividend (2.75%). Which is the better fit depends on your goals — on Pluang, investors hold The Coca-Cola Co K for 154 Days and Viatris Inc for 57 Days on average.

KOVTRS
Market Cap
$377.63B$20.03B
Volume
14,894,56814,109,977
Sector
Consumer StaplesHealth
52-Week High
$91.99$18.27
52-Week Low
$66.37$9.74
Typical Hold Time
154 Days57 Days
Enterprise Value
$404.81B$32.15B
Dividend Yield
2.42%2.75%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

The Coca-Cola Co K

Coca-Cola (KO) trades at $87.77, up 2.27% with strong technical momentum and bullish moving average signals. The company demonstrates robust fundamentals with consistent earnings beats, 28.56% net margin, and 44.23% ROE. Recent institutional buying activity and positive analyst sentiment (60% buy ratings) support the stock's upward trajectory. KO maintains its dividend aristocrat status with 64 consecutive years of dividend increases, paying $0.53 per share in the upcoming H2-26 distribution.

KO presents a compelling investment case with stable revenue growth, exceptional profitability, and strong institutional support. The stock trades at a premium valuation (P/E 26.36) but justifies it with consistent execution. Key risks include regional demand divergence in Asia and elevated debt levels. With a consensus price target of $95.75 offering 9% upside potential, KO remains a quality defensive holding for dividend-focused investors seeking stable returns.

Viatris Inc

Viatris (VTRS) trades at $17.44, down 0.29% on the day, with a bullish technical signal from moving averages and oversold short-term RSI. The company reported three consecutive quarterly earnings beats in 2026, with Q2 EPS of $0.69 beating estimates by 14.8%. Revenue for 2025 was $14.3B, though net income was negative $3.51B, reflecting margin pressure. Positive news includes a new drug approval in Japan and recognition as a top employer.

The outlook is mixed: strong cash flow generation and deleveraging support shareholder returns via dividends and buybacks, but profitability challenges and high debt levels pose risks. Analyst consensus is a 'Buy' with a $22.17 price target, implying 27% upside. Investment appeal hinges on execution of pipeline growth and margin improvement amid competitive and pricing pressures in the generics market.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

KO
17% Buy83% Sell
Avg holding period · 154 Days
VTRS
100% Buy0% Sell
Avg holding period · 57 Days

Top news

Latest headlines on both assets

About The Coca-Cola Co K

The Coca-Cola Company manufactures, markets, and distributes soft drink concentrates and syrups. The Company also distributes and markets juice and juice-drink products. Coca-Cola distributes its products to retailers and wholesalers in the United States and internationally.

Read more on KO →

About Viatris Inc

Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).

Read more on VTRS →